# PRX-3140, a 5-HT4 Partial Agonist and Sigma-1 Agonist/Antagonist, Modulates Glucocorticoid Insulin Suppression and Cortisol Levels

# B.L. Hood<sup>1</sup>, J.P. McLaughlin<sup>2</sup>, A.R. Alleyne<sup>2</sup>, J.S. Thinschmidt<sup>2</sup>, S.W. Harden7<sup>2</sup>, C.J. Frazier<sup>2</sup> J.D. Talton<sup>1\*</sup>

<sup>1</sup>Alchem Laboratories Corp. / Nanopharmaceutics, Inc., Alachua FL

<sup>2</sup>Dept. of Pharmacodynamics, College of Pharmacy, Univ. of Florida, Gainesville, FL

\*Correspondance:

James D. Talton, Ph.D. Nanopharmaceutics, Inc. 14120 NW 126 Terrace, Alachua, FL 32615 jtalton@nanopharmaceutics.com

#### 1 Abstract

2 PRX-3140 is a partial agonist to the 5-hydroxytryptamine receptor 4 (5-HT4) and a ligand for the 3 sigma-1 (S1R) and sigma-2 (S2R) receptors. Although few publications have inferred S1R 4 agonists/antagonists modulate blood glucose, Di et.al (2017) reported S1R deficiency in knockout 5 mice impacted regulation of the hypothalamic-pituitary-adrenocortical (HPA) axis, with a 6 dexamethasone-induced reduction in level of corticosterone markedly attenuated in S1R -/-7 knockout mice, implicating S1R in feedback response to the HPA axis. The hypothesis that S1R 8 deficiency causes down-regulation of the glucocorticoid receptor (GR) and attenuates GR-9 mediated feedback inhibition of HPA axis, as well as stress response of HPA axis, suggest that the 10 inverse, the activation of S1R under normal conditions, may modulate glucocorticoid insulin suppression (as a direct S1R-GR effect) as well as cortisol levels (producing HPA axis feedback 11 12 inhibition). In the present study, coadministration of 10 µM PRX-3140 with 100 nM cortisol significantly increased insulin release (to 74.8 ng/ml, P-value <0.0001). Similar effects were 13 14 observed when cells were exposed to dexamethasone (Dex), with 10 µM PRX-3140 and 10 nM 15 Dex producing 1.87-fold significantly more insulin than 10 nM Dex alone. Daily glucose concentrations in the 14-day clinical study (NCT00384423) of PRX-3140 demonstrate a reduction 16 17 for 10 mg once-daily at days 1, 7, 10, and 15. Urine free cortisol levels at 10, 30, 100 and 200 mg 18 dose levels of PRX-3140 demonstrated a larger reduction at 7 and 14 days compared to placebo. 19 As an agonist of S1R that acts as a chaperone of GR, PRX-3140 has demonstrated GR modulating 20 effects in INS-1 cells and in 14-day clinical studies in healthy adults with low incidence of side 21 effects. The results of the present study suggest that S1R activation, with PRX-3140 and NP-18-

22 2 S1R agonists, modulates glucocorticoid insulin suppression and cortisol levels.

23

24 **KEY WORDS:** PRX-3140, glucocorticoid, cortisol, insulin, diabetes.

25

#### 27 1 Introduction

PRX-3140 is a partial agonist to the 5-hydroxytryptamine receptor 4 (5-HT4) and a ligand for the 28 29 sigma-1 (S1R) and sigma-2 (S2R) receptors that has shown promise in preclinical and clinical 30 studies for its potential therapeutic effects in cognitive disorders, particularly Alzheimer's disease. [Johnson-2012]. By modulating S1R activity, PRX-3140 may enhance neuroprotective 31 32 mechanisms, improve synaptic function, and promote neuronal health, thereby addressing neurodegenerative conditions associated with cognitive deficits [Nguyen-2017]. Studies have 33 34 indicated that S1R agonists can positively influence neurotransmitter systems, including acetylcholine (ACh), which is crucial for memory and learning [van Waarde-2011]. In male Long-35 Evans rats, PRX-3140 intraperitoneal (IP) injection increased ACh output in the hippocampal 36 37 formation under "resting" and behavioral testing conditions [Johnson-2012]. Furthermore, early 38 clinical trials have suggested that PRX-3140 is well-tolerated and may lead to improvements in 39 cognitive function in patients with mild to moderate Alzheimer's disease. Continued research into 40 PRX-3140 could provide insights into its efficacy and safety, as well as its broader implications for treating cognitive impairments. 41

42 Three Phase 1 and two Phase 2 trials in 248 subjects have been conducted with PRX-3140 dosed 43 orally at 5 to 250 mg daily up to two years. Most adverse events were mild to moderate in severity. and occurred primarily in the higher dose groups, including dizziness, postural dizziness, 44 45 headache, abnormal dreams, nausea, diarrhea, dyspepsia, decreased appetite, and somnolence. Whereas earlier 5-HT4 agonists (e.g., cisapride and tegaserod) have been associated with 46 47 cardiovascular adverse events, including hERG (cardiac potassium) channel effects (QT 48 prolongation), no cardiovascular safety concerns were reported for PRX-3140. In dose escalation 49 studies, improvement in cognitive scores in subjects with mild Alzheimer's Disease were observed 50 from 5 to 50 mg delivered orally once a day. In a two-week clinical study (NCT00384423), clinical laboratory measurements demonstrated modulation of glucose levels and cortisol at low doses of 51 52 PRX-3140. However, post-hoc analysis was not performed to address this effect.

53 Drugs with S1R activity, such as haloperidol [Walter-2006], dextromethorphan [Marquard-2014], 54 and pentazocine [Kavitha-1999] have been shown to have effects on glucose levels. Only a few 55 publications have inferred that S1R agonists/antagonists modulate blood glucose levels [Paniagua-2016]. In 2017, Di et.al reported S1R deficiency in knockout mice impacted regulation of the 56 hypothalamic-pituitary-adrenocortical (HPA) axis such that acute mild restraint stress (AMRS) 57 58 induced a higher and more sustainable increase in activity of HPA axis [Di-2017]. In another 59 experiment, Dexamethasone (Dex)-induced reduction in corticosterone levels was markedly 60 attenuated in S1R -/- knockout mice, implicating S1R in glucocorticoid mediated feedback inhibition of the HPA axis. The hypothesis that S1R deficiency causes down-regulation of the 61 glucocorticoid receptor (GR) and attenuates GR-mediated feedback inhibition of HPA axis, as well 62 as stress response of HPA axis, suggest that the inverse, activation of S1R under normal conditions, 63 may modulate glucocorticoid mediated insulin suppression (direct S1R-GR effect) as well as 64 65 cortisol levels (HPA axis feedback inhibition). The present study investigated the relationship 66 between PRX-3140 and other S1R agonists to glucocorticoid insulin suppression and cortisol

levels to obtain a better understanding of these direct and indirect mechanisms compared to 5-HT4activity.

#### 69 2 Materials and Methods

#### 70 2.1 Chemicals

- 71 S1R ligands 6,7-Dihydro-4-hydroxy-7-isopropyl-6-oxo-N-(3-(piperidin-1-yl)propyl)thieno[2,3-
- b]pyridine-5-carboxamide potassium salt (PRX-3140), N-{3-[4-(4-cyclohexylmethanesulfonyl aminobutyl)-piperazin-1-yl]phenyl} acetamide hydrochloride (NP-2), and 5-((4-(6-
- 74 chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidine-1-yl)methyl)-2-fluorobenzonitrile
- 75 monofumarate (NP-3) were all synthesized in-house (Alchem Laboratories Corp.). All other
- reagents were purchased from Sigma (St. Louis, MO) unless otherwise noted.

#### 77 2.2 Receptor Binding Assays

*In vitro* radioligand competition receptor binding assays were performed to evaluate the pharmacologic profiles of PRX-3140, NP-2 and NP-3, including the S1R, S2R, a panel of serotonin receptor subtype assays (5-HT1A, 5-HT2B, and 5-HT4) and other off-target receptor subtypes. Standard receptor binding methods were employed and the majority of assays were performed using a human recombinant receptor. Where a human assay system was unavailable,

receptor binding was performed in tissue from mouse, rat, guinea pig, chicken, or bovine source.

84 Human T lymphocyte Jurkat cells and guinea pig cerebral cortex were used to prepare S1R in

85 HEPES/Tris buffer pH 7.4. PRX-3140 was incubated with 2 and 15 nM [<sup>3</sup>H] Pentazocine for 120-

- 150 minutes. Non-specific binding is estimated in the presence of  $10 \,\mu\text{M}$  Haloperidol. Membranes
- 87 were filtered and washed, and the filters then counted in a beta scintillation counter to quantify
- total binding of [<sup>3</sup>H] Pentazocine, with specific binding then calculated by subtracting non-specific
- 89 binding. Inhibition constants (Ki) values were calculated using the equation of Cheng and Prusoff
- 90 [Cheng-1973] using the observed IC50 of the tested compound, the concentration of radioligand,
- 91 and the historical values for the KD of the ligand (obtained experimentally at Eurofins Panlabs,
- 92 Inc.)  $\pm$  the standard error of the mean (SEM).

#### 93 **2.3** Acute Brain Slice Preparation and Electrophysiology Studies

94 All procedures performed on live animals as described below were reviewed and approved by the 95 Institutional Animal Care and Use Committee at the University of Florida. Animals were deeply anesthetized using a ketamine/xylazine cocktail (0.1 ml of 10% ketamine and 0.05 ml of 2% 96 97 xylazine). Brains were quickly extracted and submerged into ice-cold sucrose-laden normal 98 artificial cerebrospinal fluid (ACSF; 206 mM sucrose, 10 mM d-glucose, 1 mM MgSO<sub>4</sub>, 2 mM 99 KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 1 mM CaCl<sub>2</sub>, and 25 mM NaHCO<sub>3</sub>). A VT1000s vibratome (Leica 100 Microsystems, Buffalo Grove, IL) was used to make 300 µm coronal sections that included the 101 nucleus accumbens (NAc). Sections were maintained at 37 °C in normal ACSF (126 mM NaCl, 11 102 mM d-glucose, 1.5 mM MgSO<sub>4</sub>, 3 mM KCl, 1.2 mM NaH<sub>2</sub>PO<sub>4</sub>, 2.4 mM CaCl<sub>2</sub>, and 25mM 103 NaHCO<sub>3</sub>) and subsequently equilibrated to room temperature for a minimum of 30 minutes prior

104 to experimental use. Importantly, normal ACSF was used for incubation rather than a low- $Ca^{2+}$ 

105 ACSF (1 mM CaCl<sub>2</sub>) as NAc MSNs (medium spiny neurons) do not regain normal AP firing

- 106 function following prolonged submersion in the latter [Scala et al., 2018; Tapia et al., 2020]. All
- 107 external solutions were saturated with  $95\% O_2 / 5\% CO_2$  and had a pH of 7.3.

108 Brain slices used in whole-cell patch clamp electrophysiology studies were transferred to a

- 109 recording chamber continuously perfused at 2 mL/min with oxygenated ACSF maintained at 28°C.
- 110 Picrotoxin (PTX, 100 µM), 6,7-dinitroquinoxaline-2,3-dione (DNWX, 20 µM), and (2R)-amino-
- 111 5-phosphonovaleric acid (AP5, 40 µM) were added to ACSF to block fast synaptic currents 112
- mediated by GABAA receptors, AMPA/kainate receptors, and NMDA receptors, respectively. An
- 113 Olympus BX51WI stereomicroscope supporting infrared differential interference contrast
- 114 microscopy (IR-DIC) was used to visualize cells.
- 115 Patch pipettes (borosilicate glass capillaries 1.5 mm/0.8 mm, Sutter Instrument Company) were
- 116 made using a Flaming/Brown-type pipette puller (Sutter Instrument, P-07), and had an with an
- 117 open tip resistance of 4-6 MΩ when filled with a K-gluconate based internal solution that contained
- 118 in mM: 2 MgCl<sub>2</sub>, 0.5 EGTA, 10 HEPES, 115 K-gluconate, 10 phosphocreatine, 4 Na<sub>2</sub>-ATP, 0.4
- Na<sub>3</sub>-GTP, and 5 KCl adjusted. This solution was adjusted to pH 7.25 using KOH and volume 119
- 120 adjusted to 295 mOsm. Whole-cell recordings were made using a Multiclamp 700B amplifier,
- 121 Digidata 1440A digitizer, and Clampex 10.7 software (Molecular Devices). All whole-cell data
- 122 were sampled at 20 kHz and low-pass filtered at 2 kHz. Cells were identified as NAc MSNs based 123
- on location (proximity to the corpus collosum) and resting membrane potential ( $\leq$  -70 mV)
- 124 [Belleau and Warren, 2000; Cao et al., 2016; Willett et al., 2018; Aceto et al., 2022].
- 125 Analysis of electrophysiological recordings was performed with custom software written using
- Python 3.10 and the pyABF package [Harden, 2022] and in OriginC (OriginLab Corporation, 126 Northampton, MA). Data presented were not corrected for the liquid junction potential. Cells were 127
- excluded from analysis that had a resting membrane potential > -70 mV, that did not survive 128
- 129 through experiment completion, or that experienced a sudden change in seal quality during
- 130 recording.
- Frequency of evoked action potentials (APs) was recorded from NAc MSNs in current-clamp 131
- 132 configuration. Evoked APs were measured during a 4 second current injection starting from -100
- 133 pA with a 20 pA increase per sweep, every 10 seconds. The resting membrane potential (RMP)
- 134 was measured at the beginning of each sweep as the average voltage observed over a 3-second
- 135 period with I = 0, when cells were quiescent.

#### 136 2.4 INS-1 832/13 Rat Insulinoma Cell Line

137 The INS-1 832/13 rat insulinoma cell line was purchased from Millipore (Temecula, CA) and 138 cultured according to manufacturer instructions. Briefly, cells were thawed and expanded in 139 RPMI-1640 supplemented with L-Glutamine and 25mM HEPES (Corning, Manassas, VA), 1 mM 140 sodium pyruvate, 10 mM HEPES, 0.05 mM β-mercaptoethanol, 100 U/ml penicillin (Gibco, Grand 141 Island, NY), 100 µg/ml streptomycin (Gibco, Grand Island, NY), and 10% EmbryoMax<sup>®</sup> ES Cell 142 Qualified FBS at 37°C, 5% CO<sub>2</sub>, 95% humidity. After 2 days in culture, medium is exchanged 143 with fresh medium containing G-418 (Gibco, Grand Island, New York) at 0.3 mg/ml for selective

144 pressure. When the cells were confluent, cells were subcultured with a 1 to 6 split. For

- 145 subculturing, cells are detached using 0.25% Trypsin-EDTA (Gibco, Grand Island, NY). Passages
- 146 13 through 27 were used for the insulin release assays.

#### 147 **2.5 Insulin Secretion Assays**

148 The insulin secretion assay was based on the Millipore manufacturer insert for the INS-1 832/13 149 cells as well as the original published paper [Hohmeier, et al, 2000]. Briefly, the INS-1 832/13 150 cells were seeded in Costar 24-well TC plates (Corning, NY) at a cell density of 5X10<sup>5</sup> cells per 151 well using the expansion media without G418. Cultures were then incubated for 48 hours 37°C, 152 5% CO<sub>2</sub>, 95% humidity to confluency. The media was then replaced with fresh media containing 153 test compounds. The control wells were 2.5 mM glucose and 16.7 mM glucose with 0.1% DMSO. 154 Plates were incubated for 18 hours (37°C, 5% CO<sub>2</sub>, 95% humidity), then wells were washed with 155 HBSS twice (114 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/L KH<sub>2</sub>PO<sub>4</sub>,1.16 mmol/L MgSO<sub>4</sub>, 20 mmol/L HEPES, 2.5 mmol/L CaCl<sub>2</sub>, 25.5 mmol/L NaHCO<sub>3</sub>, and 0.2% bovine serum albumin, pH 156 157 7.2). Next HBSS containing 2.5 mM glucose was added and incubated 1 hour (37°C, 5% CO<sub>2</sub>, 158 95% humidity). Cells were then washed twice with HBSS and followed by addition of HBSS with 2.5 mM or 16.7 mM glucose, as well as test compounds diluted in 16.7 mM glucose. Note that 159 160 DMSO was supplemented in the control wells to maintain a consistent DMSO concentration (0.1%) in all wells. After a final incubation for 2 hours (37°C, 5% CO<sub>2</sub>, 95% humidity), the 161 162 supernatant was removed to measure the concentration of insulin using the ALPCO Insulin Rodent

163 (Mouse/Rat) Chemiluminescence ELISA (ALPCO, Salem NH).

#### 164 2.6 Insulin ELISA Assay

165 Insulin secretion was evaluated by using the ALPCO Insulin Rodent (Mouse/Rat) Chemiluminescence ELISA (ALPCO, Salem NH). Briefly, 75 µl of working strength conjugate 166 167 was dispensed to each well pre-coated with a monoclonal antibody specific to insulin. Next, 5 µl 168 of the standards or test samples were dispensed in duplicate. The plate was sealed and incubated 169 at room temperature for 2 hours at 700 rpm on a microplate shaker. After the incubation, the content 170 of the wells was decanted and washed 6 times with 350 µl of working strength wash buffer. After each wash, the plate was firmly tapped on absorbent paper to remove residual liquid. After the last 171 172 wash, 100 µl of working chemiluminescent substrate was dispensed into each well and incubated 173 5 minutes at room temperature. Then, 80 µl were transferred to a pureGrade<sup>™</sup> S white plate 174 (Brandtech Scientific, Dawsonville, GA). The plate is immediately read on the PerkinElmer 175 Envision multi-mode plate reader in ultra-sensitive luminescent mode.

#### 176 2.7 ATPLite Cytotoxicity Assay

177 Test compounds were diluted in DMSO. Ten nanoliters of each compound or combination of 178 compounds were dispensed to the 6 designated test wells of a Corning 1536 well TC white plate 179 (Corning, Kennebunk, ME) using a Labcyte/Beckman Coulter Echo 555 acoustic dispenser. For a 180 positive control for 100% cell death, 10 nl of 10 mM MG-132 was dispensed to the positive control wells of the assay plate (final assay concentration 25 µM) and for the negative controls (no cell 181 death), 10 nl of DMSO was dispensed to negative control wells of the assay plate. Next, the cells 182 183 were detached from the flask, centrifuged, counted on a Cytometer T4 (Nexcelom Biosciences, 184 Lawrence, MA) and resuspended in growth medium at a density of 400 cells per 4 µl. Then the

185 cells were dispensed to the assay plate using the Thermo-Scientific<sup>TM</sup> Multidrop<sup>TM</sup> Combi Reagent

186 Dispenser (4  $\mu$ l of cells in each well). The plate was centrifuged at 800rpm for 15 seconds and the

187 clear lid was replaced with a Kalypsys lid (Kalypsys, Inc. San Diego, CA) to reduce edge effects

and allow the even distribution of  $CO_2$  to all wells of the plate. The plate was incubated for 48

hours at 37°C, 5% CO<sub>2</sub>, 95% humidity. After the incubation, 4 μl of ATPlite 1step reagent (Revvity,

Waltham, MA) was dispensed into the wells using a Beckman Coulter BioRAPTR FRD. The assay plate was centrifuged at 1000rpm for 1 minute and incubated in the dark for 15 minutes at room

- 191 plate was centrifuged at 1000rpm for 1 minute and incubated in the dark for 15 minutes at room 192 temperature. The signal was then read on a Perkin Elmer Envision multi-mode plate reader in ultra-
- sensitive luminescence mode.

# 194 **2.8 Clinical Studies**

195 Data from a 14-day clinical study (NCT00384423) with PRX-3140 were analyzed (Quintiles. Inc. CRO). Each study protocol was approved by their respective investigational review board or 196 197 human subjects committee. Healthy volunteers were initially enrolled with six subjects completing 198 all treatments. Serum concentrations of PRX-3140 were determined using a validated liquid 199 chromatography coupled with tandem mass spectrometry (LC/MS/MS) method. Serum 200 concentration-time data were analyzed by noncompartmental methods using WinNonlin<sup>®</sup> 201 Professional. The first cohort to evaluate the safety, tolerability and pharmacokinetics of PRX-202 3140 was conducted in 32 healthy adult male and female volunteers from 18 to 45 years of age. 203 Each subject was administered an oral dose (capsules) of PRX-3140 or placebo once daily for 14 204 days. Eight (8) subjects were randomly assigned to each of 4 sequential dosing cohorts and 205 received either 10 mg, 30 mg, 100 mg, or 200 mg of PRX-3140 or matched placebo. If a dose 206 regimen was found to be safe and well tolerated, then the succeeding group of 8 different subjects 207 received the next higher dose of PRX-3140 (N = 6) or placebo (N = 2) for 14 days. Dose escalation 208 was dependent on safety parameters (physical examination findings, vital signs, adverse events 209 (AEs), electrocardiograms (ECGs), and clinical laboratory values including glucose and cortisol). 210 Urine free cortisol was measured by LC-MS/MS from the first morning void urine samples 211 collected at baseline (predose on Day 1) and predose on Days 7 and 14. Continuous glucose 212 monitoring (CGM) was applied in a single patient with placebo compared to 10 mg PRX-3140. 213 Clinical pharmacokinetic (PK) and pharmacodynamic (PD) sampling was performed. Subjects 214 were monitored closely throughout the study.

# 215 2.9 Statistical Analysis

216 Within groups, a paired Student's t-test was used to evaluate the effect relative to the baseline

- 217 mean. Across groups, an unpaired Student's t-test was used to compare data at matching time
- 218 points. Differences were considered significant where  $p \le 0.05$ .
- 219 For patch clamp studies, data are reported as mean ± SEM. Comparisons between groups were
- made with a one-way ANOVA in OriginPro (Originlab, Northampton, MA) using Sidak-Holm
- 221 post-hoc tests when indicated.
- 222 INS-1 832/13 rat insulinoma cell line insulin release data analysis was done using GraphPad Prism
- 223 Box and Whiskers plots graphed using the Tukey Boxplots analysis. The software calculates the
- IQR which is the inter-quartile distance (the difference between the 25th and 75th percentile). Then

adds the 75th percentile to 1.5 times the IQR. If this value is greater or equal to the largest value 225 226 in the data set, an upper whisker is drawn at the largest value. If this value is less than the largest 227 value, the upper whisker is set at the largest value less than the 75th percentile plus 1.5 times IQR. 228 Any values that are greater than this value are plotted as individual points and are considered 229 outliers for our study. For the lower whisker, the software calculates the 25th percentile minus 1.5 230 times IQR. If this value is less than the smallest data value, the whisker is drawn at to the smallest 231 data point. If the value is greater than the smallest data point, the whisker is set at the lowest value 232 greater than the 25th percentile minus 1.5 times IQR. Any values that are less than this value are 233 drawn as individual points (again, these are considered outliers for our study). The GraphPad Prism 234 software also was used to determine P values for the Student's T-tests. The percent cell death in 235 the cytotoxicity assays was determined using GeneData software (GeneData, Basel, Switzerland)

- which normalizes the data in reference to the control values.
- 237 Pharmacokinetic analysis was performed on patients who received active study treatment. AUC24
- and Cmax values reported as geometric mean (CV%). T1/2, glucose concentrations and urine free
- 239 cortisol are expressed as arithmetic mean (SD).

#### 240 **3** Results

#### 241 **3.1 5-HT and S1R Receptor Binding**

PRX-3140 was evaluated in a panel of serotonin receptor subtype assays to establish the selectivity
for 5-HT4 binding sites. PRX-3140 shows high affinity (Ki = 22nM) and selectivity for 5-HT4R
with more than 100-fold difference in affinities compared with all other 5-HT receptors tested.
PRX-3140 also has good affinity for the S1R (Ki = 79-160nM) and S2R (Ki = 40-100nM) in
receptor binding assays. The binding data for the 5-HT1A, 5-HT2B, 5-HT4, S1R, S2R activity is
listed in Table 1.

NP-18-2 is a selective full agonist to the 5-HT1A and a ligand for the S1R. NP-18-2 is a high affinity (Ki = 5.1-17 nM) 5-HT1A agonist in radioligand binding assays. NP-18-2 also demonstrates affinity for the S1R (Ki = 100 nM) in radioligand binding assays (Table 1).

- 251 NP-18-3 is a selective full antagonist to the 5-HT2B receptor and a ligand for the S1R. NP-18-3 is
- a highly selective for 5-HT2B (Ki=3.4 nM) with more than 500-fold differences in affinity for 5-
- HT2BR compared with all other 5-HT receptor subtypes tested except for the 5-HT1A receptor (5-
- HT1A, Ki = 100nM). NP-18-2 also demonstrates binding to the S2R (Ki = 42 nM) and S1R (Ki = 100 A) is the second sec
- 255 100 nM) in radioligand binding assays. NP-18-3 affinities for receptors are listed in Table 1.

#### 256 **3.2 PRX-3140 Reduces Excitability of Medium Spiny Neurons in the Nucleus Accumbens**

257 In order to determine whether PRX-3140 directly interacts with S1R in vivo, we evaluated its

ability to impact the intrinsic excitability of medium spiny neurons (MSNs) in the NAc.

259 Specifically, we performed whole-cell patch clamp recordings from visually identified MSNs in

acute tissue slices through the NAc (see methods). MSNs were injected with a series of current

pulses ranging from -120 to 800 pA, and action potential frequency in response to each stimulus was measured in current clamp. Our results revealed a concentration-dependent decrease in

maximum action potential frequency observed in response to current injection (Figure 1, one-way ANOVA,  $F_{4,24} = 17.6$ , p < 0.0001). Additional post-hoc tests revealed a significant effect of PRX-2140 vs. control at 10  $\mu$ M and 100  $\mu$ M (p<0.0001 in both cases), but not at 500 nM or 1  $\mu$ M. Overall, these effects of PRX-3140 are consistent with the reported results of other known S1R interacting compounds as described in greater detail in [Alleyne-2023].

# 268 3.3 Insulin Release Modulation by 5-HT/S1R Agonists in INS-1 832/13 Rat Insulinoma Cells

269 To examine the effect of PRX-3140 on insulin production in INS-1 832/13 cells, the cells were 270 exposed for 18 hours to varying concentrations of PRX-3140 and then starved for 1 hour with low 271 glucose (2.5 mM glucose). The test compound/compounds were then added back to the cells 272 diluted in 16.7 mM glucose. The addition of 16.7 mM glucose with 10 µM PRX-3140 or 10 nM 273 dehydroepiandrosterone (DHEA) showed a slight increase of insulin release in these cells (138.2 274 and 138.0 ng/ml, respectively compared to 113.8 ng/ml for 16.7 mM glucose with no compound) 275 but the difference was not significant (Figure 2). In our studies, 10 µM dehydroepiandrosterone 276 sulfate (DHEA-S) slightly decreased the insulin release (107.8 ng/ml compared to 112 ng/ml glucose alone). 277

To examine the effect of endogenous glucocorticoids on insulin production in INS-1 832/13 cells,

the cells were exposed to cortisol and corticosterone at physiologically relevant concentrations for 18 hours, washed with HBSS twice, starved for 1 hour with low glucose (2.5 mM glucose) and

then exposed to the glucocorticoids diluted in 16.7 mM glucose for 2 hours triggering the insulin

282 release. The amount of insulin release was then determined using the insulin ELISA assay (Figure

283 3). In these studies, 100 nM cortisol diluted in 16.7 mM glucose significantly reduced insulin

release (median value 48.8 ng/ml) compared to 16.7 mM glucose alone (median value 117.3 ng/ml;

285 p<0.0001; Student's T-test). As expected, 500 nM cortisol had more of an effect on insulin release 286 with a median value of 37 ng/ml. Corticosterone (100 nM in 16.7 mM glucose) also significantly

decreased the insulin release giving a median value 78.2 ng/ml (P value = 0.0011). If 10  $\mu$ M PRX-

288 3140 was co-administered with the 100 nM cortisol, the insulin release was significantly increased 289 (median value of 74.8 ng/ml, P<0.0001). If 1  $\mu$ M DHEA-S was co-administered with 100 nM

cortisol, there was no difference between this combination compared to 100 nM cortisol alone. If a combination of 100 nM cortisol plus 10 nM DHEA was added to the cells, the insulin release

dropped to 37.0 ng/ml which is significantly different from 100 nM cortisol alone (P value =

293 0.0015). The combination of 500 nM Cortisol plus 10 nM DHEA had a median value of 33.2 ng/ml

which is statistically the same as 500 nM cortisol (30.4 ng/ml).

295 To examine the effect of a highly potent glucocorticoid, dexamethasone (Dex) was tested in INS-296 1 832/13 cells. As described previously, chronic exposure to the compound/compounds for 18 297 hours was followed by starvation with 2.5 mM glucose and stimulation with 16.7 mM glucose 298 with and without compounds. Then, insulin released was measured in the insulin ELISA. The 299 results are shown in Figure 4. The amount of insulin produced with 10 nM Dex in the wells was 300 52.5 ng/ml while 100 nM Dex yielded 38.6 ng/ml of insulin. If 10 µM PRX-3140 was included 301 with the 10 nM Dex, significantly more insulin was produced (98.3 ng/ml, P value = 0.0124). 302 When 10 µM PRX-3140 was combined with 100 nM Dex, the amount of insulin produced was 303 62.6 ng/ml which was greater than the amount with 100 nM Dex alone but it was not considered

304 significant when the T-test analysis was performed. NP-18-2 released 138.15 ng/ml which was 305 almost identical to PRX-3140 (138.20 ng/ml). However, when combined with 10 nM Dex, NP-18-306 2 did not recover the insulin release to the extent that PRX-3140 did (76.4 ng/ml vs 98.3 ng/ml, 307 respectively). When NP-18-3 was dispensed to the cells, the median insulin production was 126.7 308 ng/ml. In combination with 10 nM Dex, NP-18-3 yielded only 40.7 ng/ml which was less than 10 309 nM Dex alone (52.4 ng/ml). However, the difference here was not significant. Cytotoxicity at 48 310 hours in INS-1 832/13 rat insulinoma cells was dose dependent based on steroid concentration 311 similar to published studies [Suksri-2022]. All S1R agonists alone were not cytotoxic (data not 312 shown).

# 313 3.4 PRX-3140 Modulates Glucocorticoid Insulin Suppression and Cortisol Levels

314 Serum concentrations of PRX-3140 were detectable after administration of a single 5 mg dose and

- all other doses tested up to 16 hours and, in general, the mean serum concentrations of PRX-3140
- 316 increased with ascending single doses of 5 to 250 mg. The PK data suggested that PRX-3140 was
- 317 absorbed at a relatively rapid rate (Tmax 1 to 2 hours) and the exposure showed moderate to high
- 318 intersubject variability median values across this dose range studied but were generally dose-
- 319 proportional. The Cmax values at the doses of 30 to 200 mg were less variable than those at the
- 320 lower doses studied (5 and 10 mg). The mean half-life (T1/2) at doses of 50 to 250 mg was 8 to 14 321 hours, respectively, suggesting the feasibility of once daily dosing. The Cmax values at the doses
- of 25 to 250 mg (CVs 34-43%) were less variable than those at the lower doses studied. Following
- multiple oral dose administration of 10, 30, 100, or 200 mg PRX-3140 for 14 days, mean exposures
- 324 (Cmax and AUC24) of PRX-3140 appeared to increase in a dose proportional manner. Dose-
- 325 related increases in the mean trough serum concentration increases were evident throughout the
- treatment period and appeared to reach steady state by approximately Day 7 for the 10, 30, and
- 327 100 mg cohorts and Day 14 for the 200 mg PRX-3140 cohort. Non-compartmental PK parameters
- are presented in Table 2.

329 Daily glucose concentrations in the 14-day study at 10, 30, 100 and 200 mg dose levels of PRX-

- 330 3140 demonstrate a reduction for 10 mg once-daily at days 1, 7, 10, and 15 (Figure 5). Because of
- the small patient number (n=6 for PRX-3140 groups) and interpatient variability, this reduction
- 332 was not statistically significant (Table 3.) Average daily glucose concentrations for placebo vs.
- 333 10mg PRX-3140 using CGM were 125 and 108 mg/dL, respectively, demonstrating a 15.6% 334 reduction (data not shown). Out-of-range % > 140 mg/dL showed a reduction for 10mg PRX-3140 compared to placebo (4.1% yrs 17% respectively) demonstrating on improvement.
- 335 3140 compared to placebo (4.1% vs. 17%, respectively), demonstrating an improvement in336 glycemic control.

337 Urine free cortisol levels in the 14-day study at 10, 30, 100 and 200 mg dose levels of PRX-3140 338 compared to placebo demonstrate a reduction at 7 and 14 days compared to initial Day 1 (Figure 339 6). In particular, 10 mg PRX-3140 demonstrated a reduction from -450 vs. 159 nmol/L at Day 7 340 and -288 vs. -57 nmol/L at Day 14 for 10mg PRX-3140 vs. placebo, respectively (Table 3). 341 Because of the small patient number (n=8) and interpatient variability, the reduction for placebo 342 vs. 10 mg PRX-3140 at Days 7 and 14 were not statistically significant (p=0.15 and 0.27, 343 respectively). 100 mg PRX-3140 demonstrated a higher reduction from -674 vs. 159 nmol/L at 344 Day 7 and -318 vs. -57 nmol/L at Day 14 for 100 mg PRX-3140 vs. placebo, respectively, but

baseline urine free cortisol at Day 1 was higher for 100 mg PRX-3140. 200 mg PRX-3140 demonstrated a reduction from -298 vs. 159 nmol/L at Day 7 and -346 vs. -57 nmol/L at Day 14 for 200 mg PRX-3140 vs. placebo, respectively, but accompanied a higher incidence of side effects. The trend for all mean PRX-3140 doses demonstrated lower cortisol levels at Day 7 and 14 compared to placebo.

#### 350 4 Discussion

Direct acting medications that lower cortisol levels include ketoconazole, metyrapone, mitotane, mifepristone, osilodrostat, and pasireotide, blocking the production or binding to the GR. All of these drugs have notable side effects, including adrenal insufficiency, headache, vomiting, nausea, fatigue, and edema (swelling caused by fluid retention), and with mifepristone abortion. As an agonist of S1R that acts as a chaperone of GR, PRX-3140 has demonstrated GR modulating effects in INS-1 cells and in 14-day clinical studies in healthy adults with low incidence of side effects.

357 Since the report that S1R knock-out mice demonstrated down-regulation of GR attenuating feedback inhibition of the HPA axis [Di-2017], the potential of S1R agonists to modulate GR-358 359 mediated insulin suppression and cortisol levels became of interest. Di et al. presented in vivo 360 evidence to show that S1R deficiency in CRF cells attenuates the GR-mediated feedback inhibition 361 of the HPA axis and facilitates the stress response of the HPA axis by down-regulation of PKC 362 signaling to suppress the GR phosphorylation. The results of the present study suggest that S1R 363 activation, with PRX-3140 and NP-18-2 S1R agonists, modulates glucocorticoid insulin 364 suppression and cortisol levels.

In receptor binding assays, PRX-3140 is highly potent (Ki = 22nM) and selective for 5-HT4R with 365 more than 100-fold difference in affinities compared with all other 5-HT receptors tested. PRX-366 3140 also displays affinity for the S1R (Ki = 79-160nM) and S2R (Ki = 40-100nM) in receptor 367 binding assays. NP-18-2 is a selective agonist for the 5-HT1A with affinity for the S1R but not 368 369 the S2R. NP-18-3 is a selective antagonist to the 5-HT2B and also demonstrates binding to the 370 S2R (Ki = 42 nM) and S1R (Ki = 100 nM). The three compounds demonstrate selectivity for 371 different 5-HT receptors and differential selectivity for S1R and S2R, with NP-18-2 with the 372 highest S1R selectivity. Binding to over 50 other receptor subtypes was low and did not overlap 373 for any one compound.

374 Receptor binding assay results cannot reflect activity, and while a cell-based assays monitoring the 375 dissociation of the sigma-1 receptor from its chaperone protein, BiP (also known as GRP78) is 376 used to determine activity [Yano et al., 2018], this assay is prone to variability based on conditions 377 and S1R ligands tested that may complicate interpretation. Therefore, to confirm the S1R activity 378 of PRX-3140, in vitro electrophysiology was used as a functional assay. Neuronal excitability on 379 NAc excitability showed a dose dependent reduction in maximum evoked AP firing similar to 380 results with the known S1R antagonist CM304 [Allyene-2023]. Notably, PRX-3140 and NP-18-2 381 demonstrate S1R antagonist activity at high doses, but reports have also shown antagonists 382 administered at low concentrations can produce the agonist-like effects [Maurice-2021].

383 Cortisol, an endogenous glucocorticoid hormone produced with a circadian daily rhythm, plays a 384 critical role in the body's stress response, but prolonged elevation of cortisol levels can lead to 385 various health issues. Cortisol is released by the adrenal cortex in response to adrenocorticotropic 386 hormone (ACTH), which is released by the pituitary in response to corticotropin-releasing hormone (CRH) released by the hypothalamus in response to stress. Chronic stress and high 387 388 cortisol levels are associated with conditions such as obesity, hypertension, diabetes, and 389 cardiovascular diseases [Abraham-2013]. Dehydroepiandrosterone (DHEA), proposed as the 390 endogenous ligand for the S1R (Ki=15 µM), is the most abundant circulating steroid in the human body produced in the adrenal gland and *de novo* in the central nervous system [Yabuki-2015]. After 391 392 smoking a cigarette, plasma ACTH and epinephrine increase, followed by cortisol and DHEA 393 reaching peak levels between 30 and 60 minutes after smoking [Mendelson-2005]. The increases 394 in cortisol and DHEA were significantly correlated, and each had a similar half-life after high 395 nicotine cigarette smoking.

396 Cortisol and DHEA interact with the S1R and can influence the expression and activity of S1R, 397 affecting neuronal health and resilience to stress [Rennekamp-2016]. The S1R is thought to play a 398 protective role in neuronal survival and stress response, and its modulation could offer therapeutic 399 avenues for addressing stress-related disorders [Penke-2018]. Cortisol suppresses insulin and 400 glucagon-like peptide-1 (GLP-1) production in the pancreas and can lead to insulin resistance 401 [Joseph-2022]. The effect of cortisol, DHEA, and the S1R agonist PRX-3140 on insulin production 402 was measured using the INS-1 832/13 rat insulinoma cell line. S1R agonists DHEA, PRX-3140 403 and NP-18-2 alone moderately increased insulin release at 10 µM, but this increase was not 404 statistically significant. 100 nM cortisol significantly reduced insulin release (48.8 ng/ml of insulin released compared to 117.3 ng/ml exposed to 16.7 mM glucose alone, P-value of <0.0001). If 10 405 406 µM PRX-3140 was co-administered with the 100 nM cortisol, the insulin release was significantly 407 increased (74.8 ng/ml, P-value <0.0001). This improvement of insulin release was not seen with 408 DHEA-S or DHEA co-administration. Co-administration of 1 µM DHEA-S with 100 nM cortisol 409 vielded no difference from 100 nM cortisol alone. Co-administration of 10 nM DHEA and 100 nM 410 cortisol drops the amount of insulin released (37.0 ng/ml) when compared to 100 nM cortisol alone 411 (48.8 ng/ml, P value = 0.0015). Similar effects were observed when cells were exposed to 412 dexamethasone, with 10 µM PRX-3140 with the 10 nM Dex producing significantly more insulin 413 than Dex alone. Dex+NP-18-2 demonstrated similar insulin release recovery to PRX-3140, 414 however, Dex+NP-18-3 (S2R ligand) did not, potentially because the concentration tested or 5-415 HT2 / S2R activity.

416 5-HT1 and 5-HT4 agonists are known to interact with the HPA. The S1R is proposed as a contributor in modulation of glucocorticoid insulin suppression and cortisol levels. PRX-3140 417 was shown to lower glucose and cortisol levels at low 10 mg daily doses up to 14 days. In a phase 418 419 I clinical study NP-18-2 demonstrated lower glucose levels at low oral doses and cortisol lowering 420 effects 1-6 hours after administration (unpublished results). PRX-3140 and NP-18-2, both S1R 421 ligands in the 100 nm range, demonstrated similar ability to improve insulin release and lower 422 cortisol levels at low doses but variable effects at higher doses in clinical studies suggesting a bi-423 phasic dose response relationship. Although 5-HT1 and 5-HT4 receptors are known to modulate

- 424 insulin release and cortisol, the biphasic dose response suggests that S1R activity is a factor.
- 425 Further clinical studies are warranted to study these effects.

### 426 5. Data Availability Statement

427 The raw data supporting the conclusions of this article will be made available by the corresponding428 author, without undue reservation.

#### 429 **6.** Conflict of Interest

JDT is an employee of Nanopharmaceutics, Inc., which holds rights in PRX-3140, NP-18-2 andNP-18-3.

#### 432 **7.** Author Contributions

BH performed experiments in INS-1 832/13 rat insulinoma cells, completed data analysis, manuscript writing, and production of final figures. JM, AA, JST, SWH, and CJF performed and assisted with the in vitro electrophysiology experiments, development of software tools for data analysis and manuscript editing. JDT wrote the initial version of the manuscript, interpreted clinical data and pharmacokinetics, assisted with direction of the project and manuscript editing.

#### 438 8. Funding

439 None.

# 440 9. Acknowledgements

441 Authors thank Gunther Hochhaus, Ph.D., Professor, Dept. of Pharmaceutics, College of Pharmacy,442 Univ. of Florida, for review.

443

- 444
- 445

.

| Ki       | 5-HT1A  | 5-HT2B | 5-HT4         | S1R           | S2R            |
|----------|---------|--------|---------------|---------------|----------------|
| PRX-3140 | >5 uM   | >5 uM  | 14.3 nM (5.4) | 10.0 nM (3.3) | 36.1 nM (16.1) |
| NP-18-2  | 5-11 nM | >5 uM  | >5 uM         | 100 nM        | >2 uM          |
| NP-18-3  | 100 nM  | 3.4 nM | >5 uM         | 110 nM        | 42 nM          |

Table 1: Receptor Binding affinity of PRX-3140, NP-18-2 and NP-18-3. Binding Ki values for
5-HT1A, 5HT2B, 5-HT4, S1R and S2R receptors were determined by using human recombinant
receptor or tissue from mouse, rat, guinea pig, chicken, or bovine source. For PRX-3140, Ki values
are reported as the geometric mean and S.E.M. based on four replicates (S.E.M. values expressed
are shown in parentheses.)

457



458

Figure 1: PRX-3140 reduces maximum firing rate of NAc MSNs in a concentrationdependent manner. *Ex vivo* application of PRX-3140 produces a dose-dependent reduction in maximum firing rate observed in NAc MSNs in response to a transient (4 second) depolarizing current injection. Open circles are individual data points and closed circles are the mean at each concentration concentration (error bars +/- SD.) A one-way-ANOVA on these data reveals a statistically significant main effect of PRX-3140 (see results for additional details). Asterisks indicate statistical significance on pairwise comparisons from post-hoc tests.



468

Figure 2: Response of INS-1 832/13 Cells to PRX-1340, DHEA and DHEA-S. After an 18 hours incubation with the test compounds, cells were washed, starved for 1 hour with 2.5 mM glucose and then exposed for 2 hours with the test compounds diluted in 16.7 mM glucose. The insulin content in the supernatant was determined by ELISA. Each condition is representative of an N of 4 (solid circles denote outliers.) Data was analyzed using GraphPad Prism using the Box and Whiskers plot.



477

478 Figure 3: Response of INS-1 832/13 Cells to Corticosterone, Cortisol, Cortisol with PRX-

479 **3140, DHEA and DHEA-S.** After an 18 hours incubation with the test compounds, cells were

480 washed, starved for 1 hour with 2.5 mM glucose and then exposed for 2 hours with the test

481 compounds diluted in 16.7 mM glucose. The insulin content in the supernatant was determined

482 by ELISA. Each condition was tested at least 4 times. Data was analyzed using GraphPad Prism

- using the Box and Whiskers plot (solid circles denote outliers.) \*\*\*\* Comparison of 100 nM
- 484 cortisol to 100nM cortisol with 10  $\mu$ M PRX-3140; P<0.0001; Student's T test.

485



488

489 Figure 4: Response of INS-1 832/13 Cells to Dexamethasone and in Combination with NP-

490 **18-2**, **NP-18-3 or PRX-3140**. After an 18 hours incubation with the test compounds, cells were

491 washed, starved for 1 hour with 2.5 mM glucose and then exposed for 2 hours with the test

492 compounds diluted in 16.7 mM glucose. The insulin content in the supernatant was determined

493 by ELISA. Each condition was tested at least 4 times. Data was analyzed using GraphPad Prism

- using the Box and Whiskers plot (solid circles denote outliers.) \* Comparison of 10nM Dex to
- 495 10 nM Dex with 10  $\mu$ M PRX-3140; P=0.01; Student's T test.

496

| PRX-3140 Dose         | 5 mg      | 10 mg      | 30 mg       | 50 mg      | 100 mg     | 200 mg     |
|-----------------------|-----------|------------|-------------|------------|------------|------------|
| <u>Day 1</u>          |           |            |             |            |            |            |
| Tmax (h)              | 2.0       | 1.5        | 1.5         | 1.0        | 1.5        | 1.0        |
| Cmax (ng/mL)          | 12.1 (62) | 55 (36)    | 76 (56)     | 301.6 (43) | 641 (56)   | 996 (38)   |
| AUC24 (ng/mL*h)       | 64 (89)   | 159 (112)  | 514 (82)    | 1718 (156) | 3766 (73)  | 4243 (46)  |
| T1/2 (h)              | 3.7 (2.4) | 4.2 (1.9)  |             | 10.3 (9.8) |            |            |
|                       |           |            |             |            |            |            |
| Day 14 (Steady-state) |           |            |             |            |            |            |
| Tmax (h)              |           | 1.5        | 1.5         |            | 1.5        | 1.5        |
| AUC24 (ng/mL*h)       |           | 533 (80)   | 879 (102)   |            | 5336 (47)  | 11850 (39) |
| Cmax (ng/mL)          |           | 77 (45)    | 149 (47)    |            | 729 (24)   | 1573 (20)  |
| Cmin (ng/mL)          |           | 13.7       | 24.9        |            | 106.2      | 165.8      |
| Cavg (ng/mL)          |           | 30.5       | 59.3        |            | 245.4      | 537.0      |
| T1/2 (h)              |           | 12.7 (7.4) | 12.7 (14.4) |            | 10.2 (2.4) | 8.6 (3.0)  |

498

499

500 Table 2 Noncompartmental PK parameters for PRX-3140. Serum pharmacokinetic parameters 501 include Tmax - Time to maximum serum concentration (h) obtained directly from the observed 502 concentration versus time data on Days 1 and 14; Cmax = Maximum serum concentration (ng/mL) 503 during the dosing interval obtained directly from the observed concentration versus time data on 504 Days 1 and 14: AUC24 = Area under the serum concentration-time curve from time zero until 24 505 hours (ng $\cdot$ h/mL), calculated by linear trapezoidal summation; Cmin = Minimum serum 506 concentration (ng/mL) during the dosing interval obtained directly from the observed 507 concentration versus time data on Day 14; Cavg = Average steady-state serum concentration calculated as AUC24 divided by the dosing interval (24 h); T1/2 = Terminal half-life (h);. CV = 508 509 coefficient of variation; SD = standard deviation. AUC24 and Cmax values reported as geometric 510 mean (CV%) and T1/2 expressed as arithmetic mean (SD).



**Figure 5: PRX-3140 effect on blood glucose.** All laboratory assessments were performed at the clinical site's certified laboratory utilizing that laboratory's normal ranges. Blood samples were collected at Screening, Day -2, 1, 2, 7, 10, 15 and following termination.

| Glucose         | Screen       | <b>Day -2</b> | <u>Day 1</u>  | Day 2      | <u>Day 7</u> | <b>Day 10</b> | <u>Day 15</u> | <u>Term.</u> |
|-----------------|--------------|---------------|---------------|------------|--------------|---------------|---------------|--------------|
| Placebo         | 86.4 (7.3)   | 89.6 (8.5)    | 88.9 (5.0)    | 88.0 (3.9) | 84.8 (4.5)   | 85.3 (5.0)    | 85.1 (3.9)    | 88.0 (5.4)   |
| 10 mg           | 88.5 (7.2)   | 90.0 (4.3)    | 83.1 (4.0)    | 89.1 (5.1) | 79.5 (4.6)   | 79.5 (5.3)    | 80.4 (4.5)    | 87.0 (6.7)   |
| 30 mg           | 93.3 (4.8)   | 92.1 (3.3)    | 87.9 (4.9)    | 87.3 (4.5) | 91.8 (3.2)   | 89.4 (2.7)    | 85.5 (2.5)    | 87.6 (5.8)   |
| 100 mg          | 92.4 (6.8)   | 93.0 (2.9)    | 88.5 (6.4)    | 87.0 (5.8) | 85.2 (4.4)   | 85.8 (5.4)    | 89.3 (7.2)    | 93.0 (9.2)   |
| 200 mg          | 90.9 (5.4)   | 92.4 (5.9)    | 90.0 (5.6)    | 90.9 (4.2) | 83.7 (2.5)   | 83.7 (2.5)    | 86.4 (4.7)    | 94.5 (1.5)   |
|                 |              |               |               |            |              |               |               |              |
| <u>Cortisol</u> | <u>Day 1</u> | <u>Day 7</u>  | <u>Day 14</u> |            |              |               |               |              |
| Placebo         | 522          | 364           | 466           |            |              |               |               |              |
|                 | (437)        | (325)         | (428)         |            |              |               |               |              |
| 10 mg           | 578          | 128           | 290           |            |              |               |               |              |
|                 | (1090)       | (127)         | (392)         |            |              |               |               |              |
| 30 mg           | 266          | 80            | 107           |            |              |               |               |              |
|                 | (297)        | (41)          | (28)          |            |              |               |               |              |
| 100 mg          | 1146         | 472           | 827           |            |              |               |               |              |
|                 | (1591)       | (513)         | (990)         |            |              |               |               |              |
| 200 mg          | 532          | 235           | 186           |            |              |               |               |              |
|                 | (1038)       | (163)         | (252)         |            |              |               |               |              |

520

521

522 **Table 3 Glucose and Urine Free Cortisol levels for PRX-3140.** All laboratory assessments were 523 performed at the clinical site's certified laboratory utilizing that laboratory's normal ranges. Blood

524 samples were collected at Screening, Day -2, 1, 2, 7, 10, 15 and following termination shown as

525 mg/dL. Glucose expressed as arithmetic mean (SD). Urine Free Cortisol levels were collected pre-

526 dose at Day 1, 7, and 14 shown as nmol/L. Urine Free Cortisol expressed as arithmetic mean (SD).





530

529

**Figure 6:** Urine Free Cortisol on Days 7 and 14. Urine Free Cortisol in Subjects pre-dose on Day 1, 7 and Day 14 with oral administration of 10 mg (n=6), 30 mg (n=6), 100 mg (n=6), 200 mg (n=6) PRX-03140 or Placebo (n=8) for 14 days.

#### 535 References

- Johnson DE, Drummond E, Grimwood S, Sawant-Basak A, Miller E, Tseng E, McDowell LL,
   Vanase-Frawley MA, Fisher KE, Rubitski DM, Stutzman-Engwall KJ, Nelson RT, Horner WE,
   Gorczyca RR, Hajos M, Siok CJ. The 5-hydroxytryptamine4 receptor agonists prucalopride
   and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the
- 540 power of stimulated hippocampal  $\theta$  oscillations. J Pharmacol Exp Ther. 2012 Jun;341(3):681-541 91. doi: 10.1124/jpet.112.192351. Epub 2012 Mar 9. PMID: 22408061
- Nguyen L, Lucke-Wolds BP, Mookerjee S, Kaushal N, Matsumoto RR. Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection. Adv Exp Med Biol. 2017;964:133–152. doi: 10.1007/978-3-319-50174-1 10
- van Waarde AV, Ramakrishnan NK, Rybczynska AA, Elsinga PH, Ishiwata K, Nijholt IM,
   Luiten PG, Dierckx RA. The cholinergic system, sigma-1 receptors and cognition. Behavioural
   Brain Research. Volume 221, Issue 2, 10 August 2011, Pages 543-554
- 4. Walter RB, Hoofnagle AN, Lanum SA, Collins SJ. Acute, life-threatening hypoglycemia associated with haloperidol in a hematopoietic stem cell transplant recipient. Bone Marrow Transplant. 2006 Jan;37(1):109-10. doi: 10.1038/sj.bmt.1705187. PMID: 16247427
- Marquard J, Otter S, Welters A, Stirban A, Fischer A, Eglinger J, Herebian D, Kletke O, Klemen MS, Stožer A, Wnendt S, Piemonti L, Köhler M, Ferrer J, Thorens B, Schliess F, Rupnik MS, Heise T, Berggren PO, Klöcker N, Meissner T, Mayatepek E, Eberhard D, Kragl M, Lammert E. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nat Med. 2015 Apr;21(4):363-72. doi: 10.1038/nm.3822. Epub 2015 Mar 16. PMID: 25774850
- Kavitha J, Arumugam V, Prabakaran E. Influence of Pentazocine on Serum Lipids and Selected
   Enzymes of Male Wistar Rats J. Clin. Biochem. Nutr., 27, 1-7, 1999.
- 7. Paniagua JA. Nutrition, insulin resistance and dysfunctional adipose tissue determine the
  different components of metabolic syndrome. World J Diabetes. 2016 Nov 15;7(19):483-514.
  doi: 10.4239/wjd.v7.i19.483. PMID: 27895819
- B. Di T, Zhang S, Hong J, Zhang T, Chen L. Hyperactivity of Hypothalamic-Pituitary-Adrenal Axis Due to Dysfunction of the Hypothalamic Glucocorticoid Receptor in Sigma-1 Receptor Knockout Mice. Front Mol Neurosci. 2017 Sep 6;10:287. doi: 10.3389/fnmol.2017.00287.
   eCollection 2017. PMID: 28932185
- 567 9. Cheng YC, Prusoff WH. Relationship between the inhibition constant (KI) and the
  568 concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
  569 Biochemical Pharmacology. Volume 22, Issue 23, 1 December 1973, Pages 3099-3108
- 570 10. Scala F et al. Environmental Enrichment and Social Isolation Mediate Neuroplasticity of
  571 Medium Spiny Neurons through the GSK3 Pathway. Cell Reports. 2018 Apr 10;23(2):555572 567. doi: 10.1016/j.celrep.2018.03.062. PMID: 29642012
- 573 11. Tapia CM, Folorunso O, Singh AK, McDonough K, Laezza F. Effects of Deltamethrin Acute
- 574 Exposure on Nav1.6 Channels and Medium Spiny Neurons of the Nucleus Accumbens.
- 575 Toxicology. 2020 Jul:440:152488. doi: 10.1016/j.tox.2020.152488. Epub 2020 May 6. PMID:
  576 32387285

577 12. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S,
578 Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak
579 P, Cardona A. Fiji: an open-source platform for biological-image analysis. 2012. Nat Methods
580 9:676–682.

- 581 13. Belleau ML, Warren RA. Postnatal Development of Electrophysiological Properties of
   582 Nucleus Accumbens Neurons. 2000. J Neurophysiol 84:2204–2216.
- 14. Cao J, Dorris DM, Meitzen J. Neonatal Masculinization Blocks Increased Excitatory Synaptic
   Input in Female Rat Nucleus Accumbens Core. 2016. Endocrinology 157:3181–3196.
- 585 15. Willett JA, Johnson AG, Vogel AR, Patisaul HB, McGraw LA, Meitzen J. Nucleus accumbens
  586 core medium spiny neuron electrophysiological properties and partner preference behavior in
  587 the adult male prairie vole, Microtus ochrogaster. 2018. J Neurophysiol 119:1576–1588.
- 16. Aceto G, Nardella L, Lazzarino G, Tavazzi B, Bertozzi A, Nanni S, Colussi C, D'Ascenzo M,
  Grassi C. Acute restraint stress impairs histamine type 2 receptor ability to increase the
  excitability of medium spiny neurons in the nucleus accumbens. 2022. Neurobiol Dis
  175:105932.
- 592 17. Harden SW, pyabf 2.3.7. Available at: <u>https://pypi.org/project/pyabf</u>. 2022.
- 18. Marino M, Misuri L, Brogioli D. A new open source software for the calculation of the liquid
   junction potential between two solutions according to the stationary Nernst-Planck equation.
   Arxiv. arXiv:1403.3640 [physics.chem-ph] 2014.
- 596 19. Golowasch J, Thomas G, Taylor AL, Patel A, Pineda A, Khalil C, Nadim F. Membrane
  597 Capacitance Measurements Revisited: Dependence of Capacitance Value on Measurement
  598 Method in Nonisopotential Neurons. 2009. J Neurophysiol 102:2161–2175.
- 20. Cirino TJ, Harden SW, McLaughlin JP, Frazier CJ. Region-specific effects of HIV-1 Tat on
   intrinsic electrophysiological properties of pyramidal neurons in mouse prefrontal cortex and
   hippocampus. 2020. J Neurophysiol 123:1332–1341.
- Shen W, Hernandez-Lopez S, Tkatch T, Held JE, Surmeier DJ. Kv1.2-Containing K+ Channels
   Regulate Subthreshold Excitability of Striatal Medium Spiny Neurons. 2004. J Neurophysiol
   91:1337–1349.
- 22. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of
  INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent
  glucose-stimulated insulin secretion. Diabetes. 2000 Mar;49(3):424-30. doi:
  10.2337/diabetes.49.3.424. PMID: 10868964
- 23. Alleyne AR. A Mechanistic Interrogation of the Sigma-1 Receptor as a Potential Target for
  Psychostimulant Use Disorder. Dissertation. 2023. https://originalufdc.uflib.ufl.edu/UFE0059777/00001
- 612 24. Abraham SB, Rubino D, Sinaii N, Ramsey S, Nieman LK. Cortisol, obesity and the metabolic
  613 syndrome: A cross-sectional study of obese subjects and review of the literature. Obesity
  614 (Silver Spring). 2013 Jan;21(1):E105–E117. doi: 10.1002/oby.20083. PMID: 23505190
- 615 25. Suksri K, Semprasert N, Limjindaporn T, Yenchitsomanus PT, Kooptiwoot S, Kooptiwut S.
  616 Cytoprotective effect of genistein against dexamethasone-induced pancreatic beta-cell
  617 apoptosis. Sci Rep. 2022 Jul 28;12(1):12950. doi: 10.1038/s41598-022-17372-z. PMID:
  618 35902739

- 619 26. Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1
  620 receptor ligands for the treatment of neurodegenerative disorders. Expert Opinion on Drug
  621 Discovery, 16:4, 373-389, DOI: 10.1080/17460441.2021.1838483
- 27. Yabuki Y, Shinoda Y, Izumi H, Ikuno T, Shioda N, Fukunaga K. Dehydroepiandrosterone
  administration improves memory deficits following transient brain ischemia through sigma-1
  receptor stimulation. Brain Res. 2015 Oct 5;1622:102-13. doi: 10.1016/j.brainres.2015.05.006.
  Epub 2015 Jun 25. PMID: 26119915
- 28. Rennekamp AJ, Huang XP, Wang Y, Patel S, Lorello PJ, Cade L, Gonzales AP, Yeh JR,
  Caldarone BJ, Roth BL, Kokel D, Peterson RT. Sigma-1 receptor ligands control a switch
  between passive and active threat responses. Nat Chem Biol. 2016 May 30;12(7):552–558.
  doi: 10.1038/nchembio.2089. PMID: 27239788.
- 630 29. Penke B, Fülöp L, Szűcs M, Frecska E. The Role of Sigma-1 Receptor, an Intracellular
  631 Chaperone in Neurodegenerative Diseases. Curr Neuropharmacol. 2018 Jan;16(1):97–116.
  632 PMID: 28554311
- 30. Joseph AM and Janssen JL. New Insights into the Role of Insulin and Hypothalamic-PituitaryAdrenal (HPA) Axis in the Metabolic Syndrome. Int J Mol Sci. 2022 Jul 25;23(15):8178. doi:
  10.3390/ijms23158178. PMID: 35897752
- 31. Yano H, Bonifazi A, Xu M, Guthrie DA, Schneck SN, Abramyan AM, Fant AD, Hong WC,
  Newman AH, Shi L. Pharmacological Profiling of Sigma 1 Receptor Ligands by Novel
  Receptor Homomer Assays. Neuropharmacology. 2018 Jan 31;133:264–275. doi:
  10.1016/j.neuropharm.2018.01.042. PMID: 29407216.